TDEN F17

TDEN F17 (Tetravalent Dengue Vaccine F17) is a live-attenuated tetravalent dengue vaccine developed by the Walter Reed Army Institute of Research (WRAIR) in collaboration with GSK, under the U.S. Army Medical Research and Development Command. The vaccine contains four attenuated dengue virus strains representing all four serotypes: DENV-1 (45AZ5), DENV-2 (S16803), DENV-3 (CH53489), and DENV-4 (341750). These strains were obtained from natural infections and attenuated through serial passages in primary dog kidney (PDK) cells. The vaccine is administered as a two-dose regimen given 180 days apart and has been shown to be safe and immunogenic in individuals ranging from 12 months to 50 years of age. The F17 formulation was developed as an optimization of the earlier F17pre formulation to improve neutralizing antibody responses and long-term immunity.

Other names

Tetravalent Dengue Vaccine F17WRAIR/GSK dengue vaccine